首页> Molecular pharmaceutics> Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab.

Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab.

导出原文传递

翻译打印收藏纠错

第一作者： Anna,Orlova

第一单位： Department of Medicinal Chemistry , Uppsala University , Uppsala , Sweden.;Science for Life Laboratory , Uppsala University , Uppsala , Sweden.

作者： Anna,Orlova ^[1] ; Tarek Z,Bass ^[2] ; Sara S,Rinne ^[3] ; Charles Dahlsson,Leitao ^[2] ; Maria,Rosestedt ^[3] ; Christina,Atterby ^[4] ; Lindvi,Gudmundsdotter ^[5] ; Fredrik Y,Frejd ^[6] ; John,Löfblom ^[2] ; Vladimir,Tolmachev ^[4] ; Stefan,Ståhl ^[2]

作者单位： Department of Medicinal Chemistry , Uppsala University , Uppsala , Sweden.;Science for Life Laboratory , Uppsala University , Uppsala , Sweden. ^[1] Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health , KTH Royal Institute of Technology , Stockholm , Sweden. ^[2] Department of Medicinal Chemistry , Uppsala University , Uppsala , Sweden. ^[3] Department of Immunology, Genetics and Pathology , Uppsala University , Uppsala , Sweden. ^[4] Affibody AB , Solna , Sweden. ^[5] Department of Immunology, Genetics and Pathology , Uppsala University , Uppsala , Sweden.;Affibody AB , Solna , Sweden. ^[6]

关键词 HER3 affibody molecule preclinical targeting therapy